Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cannabinoid Receptor Type 2 (CB2) Agonist Pipeline Insight, 2018 Report - ResearchAndMarkets.com

Research and Markets
Posted on: 26 Feb 18

The "Cannabinoid Receptor Type 2 (CB2) Agonist -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

'Cannabinoid Receptor Type 2 (CB2) Agonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cannabinoid Receptor Type 2 (CB2) Agonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Cannabinoid Receptor Type 2 (CB2) Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Cannabinoid Receptor Type 2 (CB2) Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Cannabinoid Receptor Type 2 (CB2) Agonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Cannabinoid Receptor Type 2 (CB2) Agonist

4. Comparative Analysis

5. Cannabinoid Receptor Type 2 (CB2) Agonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Cannabinoid Receptor Type 2 (CB2) Agonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • NEOMED
  • Arena Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/v37xq9/cannabinoid?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005976/en/

Business Wire
www.businesswire.com

Last updated on: 26/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.